Literature DB >> 67784

Histamine release in dogs by Cremophor E1 and its derivatives: oxethylated oleic acid is the most effective constituent.

W Lorenz, H J Reimann, A Schmal, P Dormann, B Schwarz, E Neugebauer, A Doenicke.   

Abstract

Several preparations of Cremophor E1, several of other non-ionic detergents and several components of Cremophor E1 were tested for their histamine-releasing capacity in dogs. Lutensol AP 10 and a derivative of 1,2-propylenglycol were ineffective, but showed excellent properties as detergents. Thus the histamine-releasing capacity was not necessarily combined with the tenside effect of the surfactants. Oleic acid found in Tween 80 as well as in Cremophor E1 seems to be the most effective constituent, but the alcohol seems also to be important for the histamine-releasing capacity. The development of a non-toxic solubilizer for lipophilic drugs seems of considerable clinical interest.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 67784     DOI： 10.1007/BF01964882

Source DB:  PubMed          Journal:  Agents Actions        ISSN： 0065-4299


  7 in total

1.  Histamine release after intravenous application of short-acting hypnotics. A comparison of etomidate, Althesin (CT1341) and propanidid.

Authors:  A Doenicke; W Lorenz; R Beigl; H Bezecny; G Uhlig; L Kalmar; B Praetorius; G Mann
Journal:  Br J Anaesth       Date:  1973-11       Impact factor: 9.166

2.  An improved method for the determination of histamine release in man: its application in studies with propanidid and thiopentone.

Authors:  W Lorenz; A Doenicke; R Meyer; H J Reimann; J Kusche; H Barth; H Geesing; M Hutzel; B Weissenbacher
Journal:  Eur J Pharmacol       Date:  1972-08       Impact factor: 4.432

3.  Histamine release in man by propanidid and thiopentone: pharmacological effects and clinical consequences.

Authors:  W Lorenz; A Doenicke; R Meyer; H J Reimann; J Kusche; H Barth; H Geesing; M Hutzel; B Weissenbacher
Journal:  Br J Anaesth       Date:  1972-04       Impact factor: 9.166

4.  Florometric histamine determination in canine plasma under normal conditions, following application of exogenous histamine, and during histamine release by haemaccel.

Authors:  W Lorenz; H Barth; M Thermann; A Schmal; P Dormann; I Niemeyer
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1974-09

5.  Evaluation of histamine elimination curves in plasma and whole blood of several circulatory regions: a method for studying kinetics of histamine release in the whole animal.

Authors:  W Lorenz; M Thermann; K Messmer; A Schmall; P Dormann; J Kusche; H Barth; R Tauber; M Hutzel; G Mann; R Uhlig
Journal:  Agents Actions       Date:  1974-12

Review 6.  Histamine release in man.

Authors:  W Lorenz
Journal:  Agents Actions       Date:  1975-12

7.  Adverse reactions to intravenous anaesthetics.

Authors:  R S Clarke; J w Dundee; F T Garrett; G K McArdle; J A Sutton
Journal:  Br J Anaesth       Date:  1975-05       Impact factor: 9.166
  7 in total
  37 in total

Review 1.  Role of formulation vehicles in taxane pharmacology.

Authors:  L van Zuylen; J Verweij; A Sparreboom
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

2.  Administration of substances to laboratory animals: equipment considerations, vehicle selection, and solute preparation.

Authors:  Patricia V Turner; Cynthia Pekow; Mary Ann Vasbinder; Thea Brabb
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-09       Impact factor: 1.232

3.  Influence of H1- and H2-receptor antagonists on the circulatory system and on the endogenous plasma histamine concentrations in dogs.

Authors:  M Thermann; W Lorenz; A Schmal; F Schingale; P Dormann; H Hamelmann
Journal:  Agents Actions       Date:  1977-03

4.  Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy.

Authors:  Feihu Wang; Michael Porter; Alexandros Konstantopoulos; Pengcheng Zhang; Honggang Cui
Journal:  J Control Release       Date:  2017-09-25       Impact factor: 9.776

5.  PEGylated lipid microspheres loaded with cabazitaxel for intravenous administration: stability, bioavailability, antitumor efficacy, and toxicity.

Authors:  Yang Liu; Bin Xie; Lin Li; Xinyu Zhang; Yu Zhang; Haibing He; Tian Yin; Xing Tang; Cuifang Cai; Jingxin Gou
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

6.  [The role of metabolic acidosis in alphathesin-induced tachypnea in dogs].

Authors:  S Bergeret; J H Gaudy; J F Boitier; F Ferracci
Journal:  Can Anaesth Soc J       Date:  1984-05

7.  Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems.

Authors:  Jun Yang; Donald E Mager; Robert M Straubinger
Journal:  AAPS J       Date:  2009-11-10       Impact factor: 4.009

8.  Polymeric micelles for the pH-dependent controlled, continuous low dose release of paclitaxel.

Authors:  Adam W G Alani; Younsoo Bae; Deepa A Rao; Glen S Kwon
Journal:  Biomaterials       Date:  2009-12-03       Impact factor: 12.479

9.  Embedded multicellular spheroids as a biomimetic 3D cancer model for evaluating drug and drug-device combinations.

Authors:  Kristie M Charoen; Brian Fallica; Yolonda L Colson; Muhammad H Zaman; Mark W Grinstaff
Journal:  Biomaterials       Date:  2013-12-19       Impact factor: 12.479

Review 10.  Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer.

Authors:  Evelina Miele; Gian Paolo Spinelli; Ermanno Miele; Federica Tomao; Silverio Tomao
Journal:  Int J Nanomedicine       Date:  2009-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.